US Stock MarketDetailed Quotes

GNMSF GENMAB AS

Watchlist
  • 274.350
  • +4.480+1.66%
15min DelayClose Apr 26 16:00 ET
17.79BMarket Cap28.88P/E (TTM)

About GENMAB AS Company

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Company Profile

SymbolGNMSF
Company NameGENMAB AS
Listing DateJul 18, 2019
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketPink Market
Employees2204
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jan G. J. van de Winkel, PhD
  • President and Chief Executive Officer
  • 44.30M
  • Christopher Cozic
  • Executive Vice President and Chief People Officer
  • 13.20M
  • Dr. Judith Klimovsky
  • Executive Vice President and Chief Development Officer
  • 21.70M
  • Birgitte Stephensen
  • Executive Vice President and Chief Legal Officer
  • 10.10M
  • Dr. Martine J. van Vugt, PhD
  • Executive Vice President and Chief Strategy Officer
  • 8.90M
  • Anthony Mancini
  • Executive Vice President and Chief Operating Officer
  • 21.80M
  • Anthony Pagano
  • Executive Vice President and Chief Financial Officer
  • 19.60M
  • Dr. Tahamtan Ahmadi, PhD
  • Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
  • 19.80M
  • Dr. Mijke Zachariasse
  • Director, Vice President and Head of Antibody Research Materials
  • 1.10M
  • Deirdre P. Connelly
  • Chairman of the Board
  • 2.80M
  • Pernille Erenbjerg
  • Deputy Chairman of the Board
  • 2.10M
  • Anders Gersel Pedersen, M.D.,PhD
  • Director
  • 1.70M
  • Takahiro Hamatani
  • Director and Senior Director, Finance Japan
  • 800.00K
  • Martin Schultz
  • Director, Senior Director and Head of Development Business Partnership and Strategy
  • 800.00K
  • Rolf Karl-Heinz Hoffmann
  • Independent Director
  • 1.50M
  • Dr. Paolo Paoletti, M.D.
  • Independent Director
  • 1.50M
  • Elizabeth G. O’Farrell
  • Independent Director
  • 1.90M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg